%0 Journal Article
%T Case management to improve adherence for HIV-infected patients receiving antiretroviral therapy in Ethiopia: a micro-costing study
%A Elliot A Marseille
%A Sebastian Kevany
%A Ismael Ahmed
%A Getachew Feleke
%A Bill Graham
%A Thomas Heller
%A James G Kahn
%A Michael Reyes
%J Cost Effectiveness and Resource Allocation
%D 2011
%I BioMed Central
%R 10.1186/1478-7547-9-18
%X This study applied standard micro-costing methods to identify the incremental costs of the CM program. We divided total CM-attributable costs by three output measures (patient-quarters of CM services delivered, number of patients served and successful patient exits) to derive three separate indices of unit costs. The relationships between unit costs and two operational factors (scale and service-volume to staff ratios) were quantified through bivariate analyses.The CM program delivered 4,598 patient-quarters of services, serving 5,056 patients and 1,995 successful exits at a cost of $167,457 over 12 months, or $36 per patient-quarter, $33 per patient served and $84 per successful exit from the CM program. Among the 14 sites, mean costs were $11,961 (sd, $3,965) for the 12-month study period, and $51 (sd, $36) per patient-quarter; $48 (sd, $32) per patient served; and $183 (sd, $157) per successful exit. Unit costs varied inversely with scale (r, -0.70 for cost per patient-quarter versus patient-quarters of service) and with the service-volume to staff ratio (r, -0.68 for cost per patient-quarter versus staff per patient-quarter).For those receiving CM, the program adds 0.52% to the lifetime cost of ART. These data reflect wide variation in unit costs among the study sites and suggest that high patient volume may be a major determinant of CM program efficiency. The observed variations in unit costs also indicate that there may be opportunities to identify staffing patterns that increase overall program efficiency.Over 1.1 million HIV-infected individuals reside in Ethiopia [1]. Adult HIV prevalence was estimated at 1.8% to 2.2% in 2009, low by the standards of sub-Saharan Africa [2]. Provision of free antiretroviral therapy (ART) started in October 2005, leveraging support from both the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) and the United States President's Emergency Plan for AIDS Relief (PEPFAR) [3]. Ethiopia is among PEPFAR's 15 most highly-fu
%U http://www.resource-allocation.com/content/9/1/18